DÄ internationalArchiveReferences
References

Review article

Sleep-Related Disorders in Neurology and Psychiatry

Dtsch Arztebl Int 2019; 116: 681-8. DOI: 10.3238/arztebl.2019.0681

Rémi, J; Pollmächer, T; Spiegelhalder, K; Trenkwalder, C; Young, P

1.American Academy of Sleep Medicine. The International Classification of Sleep Disorders – Third Edition (ICSD-3). Darien, Il, Il: American Academy of Sleep Medicine; 2014.
2.Pollmächer T, Wetter TC, Happe S, Richter K, Acker J, Riemann D: Schlafmedizinische Differenzialdiagnostik in Psychiatrie und Psychotherapie. Nervenarzt 2014; 85: 57–66 CrossRef MEDLINE
3.Morin CM, Drake CL, Harvey AG, et al.: Insomnia disorder. Nat Rev Dis Prim 2015; 1: 15026 CrossRef MEDLINE
4.Kucharczyk ER, Morgan K, Hall AP: The occupational impact of sleep quality and insomnia symptoms. Sleep Med Rev 2012; 16: 547–59 CrossRef MEDLINE
5.Riemann D, Baum E, Cohrs S, et al.: S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen Kapitel „Insomnie bei Erwachsenen“. Somnologie 2017; 21: 2–44 CrossRef
6.Riemann D, Baglioni C, Bassetti C, et al.: European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017; 26: 675–700 CrossRef MEDLINE
7.Pollmächer T, Wetter TC: Schlafstörungen und psychische Erkrankungen. Stuttgart: Kohlhammer; 2017. 223 p.
8.Everitt H, Baldwin DS, Stuart B, et al.: Antidepressants for insomnia in adults. Cochrane Database Syst Rev 2018; 5: CD010753 CrossRef MEDLINE PubMed Central
9.Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M: Eszopiclone for insomnia. Cochrane Database Syst Rev 2018; 10: CD010703 CrossRef
10.Mayer G, Arzt M, Braumann B, et al.: S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen Kapitel „Schlafbezogene Atmungsstörungen bei Erwachsenen“. Somnologie 2017; 20 (Suppl s2): S97–180 CrossRef
11.DGSM: S3-Leitlinie. Somnologie – Schlafforsch und Schlafmedizin 2009; 13 (S1): 1–160 CrossRef
12.Ruoff C, Rye D: The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality. Curr Med Res Opin 2016; 32: 1–12 CrossRef MEDLINE
13.Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE: The neurobiological basis of narcolepsy. Nat Rev Neurosci 2019; 20: 83–93 CrossRef MEDLINE PubMed Central
14.Billiard M, Sonka K: Idiopathic hypersomnia. Sleep Med Rev 2016; 29: 23–33 CrossRef MEDLINE
15.Derry CP, Davey M, Johns M, et al.: Distinguishing sleep disorders from seizures: diagnosing bumps in the night. Arch Neurol 2006; 63: 705–9 CrossRef MEDLINE
16.Stallman HM, Kohler M: Prevalence of sleepwalking: a systematic review and meta-analysis. Arez AP, editor. PLoS One 2016; 11: e0164769 CrossRef MEDLINE PubMed Central
17.Stallman HM, Kohler M, White J: Medication induced sleepwalking: a systematic review. Sleep Med Rev 2018; 37: 105–13 CrossRef MEDLINE
18.Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH: The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. Mov Disord 2007; 22: 2386–93 CrossRef MEDLINE
19.Schenck CH, Boeve BF, Mahowald MW: Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med 2013; 14: 744–8 CrossRef MEDLINE
20.Allen RP, Picchietti D, Hening WA, et al.: Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101–19 CrossRef
21.Bartl M, Winkelmann J, Högl B, Paulus W, Trenkwalder C: Häufige neurologische Erkrankungen assoziiert mit dem Restless-legs-Syndrom. Nervenarzt. 2018; 89: 1156–64 CrossRef MEDLINE
22.Winkelmann J, Allen RP, Högl B, et al.: Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017). Mov Disord 2018; 33: 1077–91 CrossRef MEDLINE
23.Allen RP, Chen C, Garcia-Borreguero D, et al.: Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 2014; 370: 621–31 CrossRef MEDLINE
24.de Oliveira CO, Carvalho LB, Carlos K, et al.: Opioids for restless legs syndrome. Cochrane Database Syst Rev 2016; 6: CD006941 CrossRef
25.Buysse DJ: Insomnia. JAMA 2013; 309: 706 CrossRef MEDLINE PubMed Central
e1.Morin CM, Bélanger L, LeBlanc M, et al.: The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med 2009; 169: 447–53 CrossRef MEDLINE
e2.Kyle SD, Morgan K, Espie CA: Insomnia and health-related quality of life. Sleep Med Rev 2010; 14: 69–82 CrossRef MEDLINE
e3.Fortier-Brochu E, Beaulieu-Bonneau S, Ivers H, Morin CM: Insomnia and daytime cognitive performance: a meta-analysis. Sleep Med Rev 2012; 16: 83–94 CrossRef MEDLINE
e4.Li M, Zhang X-W, Hou W-S, Tang Z-Y: Insomnia and risk of cardiovascular disease: a meta-analysis of cohort studies. Int J Cardiol 2014; 176: 1044–7 CrossRef MEDLINE
e5.Anothaisintawee T, Reutrakul S, Van Cauter E, Thakkinstian A: Sleep disturbances compared to traditional risk factors for diabetes development: Systematic review and meta-analysis. Sleep Med Rev 2016; 30: 11–24 CrossRef MEDLINE
e6.Baglioni C, Battagliese G, Feige B, et al.: Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord 2011; 135: 10–9 CrossRef MEDLINE
e7.Pigeon WR, Pinquart M, Conner K: Meta-analysis of sleep disturbance and suicidal thoughts and behaviors. J Clin Psychiatry 2012; 73: e1160–7 CrossRef MEDLINE
e8.Shi L, Chen S-J, Ma M-Y, et al.: Sleep disturbances increase the risk of dementia: a systematic review and meta-analysis. Sleep Med Rev 2018; 40: 4–16 CrossRef MEDLINE
e9.Morphy H, Dunn KM, Lewis M, Boardman HF, Croft PR: Epidemiology of insomnia: a longitudinal study in a UK population. Sleep 2007; 30: 274–80.
e10.Weissman MM, Greenwald S, Niño-Murcia G, Dement WC: The morbidity of insomnia uncomplicated by psychiatric disorders. Gen Hosp Psychiatry 1997; 19: 245–50 CrossRef
e11.Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD: Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016; 165: 125–33 CrossRef MEDLINE
e12.van Straten A, van der Zweerde T, Kleiboer A, Cuijpers P, Morin C, Lancee J: Cognitive and behavioral therapies in the treatment of insomnia: a meta-analysis. Sleep 2018; 38: 3–16 CrossRef MEDLINE
e13.Nissen C, Frase L, Hajak G, Wetter TC: Hypnotika – Stand der Forschung. Nervenarzt. 2014; 85: 67–76 CrossRef MEDLINE
e14.Ho FYY, Chan CS, Tang KNS: Cognitive-behavioral therapy for sleep disturbances in treating posttraumatic stress disorder symptoms: a meta-analysis of randomized controlled trials. Clin Psychol Rev 2016; 43: 90–102 CrossRef MEDLINE
e15.Johnson JA, Rash JA, Campbell TS, et al.: A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors. Sleep Med Rev 2016; 27: 20–8 CrossRef MEDLINE
e16.Tang NKY, Lereya ST, Boulton H, Miller MA, Wolke D, Cappuccio FP: Nonpharmacological treatments of insomnia for long-term painful conditions: a systematic review and meta-analysis of patient-reported outcomes in randomized controlled trials. Sleep 2015; 38: 1751–64 CrossRef MEDLINE PubMed Central
e17.Rösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M: Eszopiclone for insomnia. Cochrane Database Syst Rev 2018; 10: CD010703 CrossRef
e18.Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL: Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev 2017; 34: 10–22 CrossRef MEDLINE
e19.Winokur A, DeMartinis NA, McNally DP, Gary EM, Cormier JL, Gary KA: Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003; 64: 1224–9 CrossRef MEDLINE
e20.Karsten J, Hagenauw LA, Kamphuis J, Lancel M: Low doses of mirtazapine or quetiapine for transient insomnia: a randomised, double-blind, cross-over, placebo-controlled trial. J Psychopharmacol 2017; 31: 327–37 CrossRef MEDLINE
e21.Hajak G, Rodenbeck A, Voderholzer U, et al.: Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 2001; 62: 453–63 CrossRef MEDLINE
e22.Krystal AD, Durrence HH, Scharf M, et al.: Efficacy and safety of Doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 2010; 33: 1553–61 CrossRef MEDLINE PubMed Central
e23.Riemann D, Voderholzer U, Cohrs S, et al.: Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry 2002; 35: 165–74 CrossRef MEDLINE
e24.Statistisches Bundesamt. Mikrozensus 2017. www.destatis.de (last accessed on 9 April 2019)
e25.Reid KJ, Abbott SM: Jet lag and shift work disorder. Sleep Med Clin 2015; 10: 523–35 CrossRef MEDLINE
e26.Morgenthaler TI, Lee-Chiong T, Alessi C, et al.: Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An american academy of sleep medicine report. Sleep 2007; 30: 1445–59 CrossRef MEDLINE PubMed Central
e27.Emens JS, Laurie AL, Songer JB, Lewy AJ: Non-24-hour disorder in blind individuals revisited: variability and the influence of environmental time cues. Sleep 2013; 36: 1091–100 CrossRef MEDLINE PubMed Central
e28.Emens JS, Eastman CI: Diagnosis and treatment of non-24-h sleep-wake disorder in the blind. Drugs 2017; 77: 637–50 CrossRef MEDLINE
e29.Li T, Jiang S, Han M, et al.: Exogenous melatonin as a treatment for secondary sleep disorders: a systematic review and meta-analysis. Front Neuroendocrinol 2018; 52: 22–8 CrossRef MEDLINE
e30.Quera Salva MA, Hartley S, Léger D, Dauvilliers YA: Non-24-hour sleep–wake rhythm disorder in the totally blind: diagnosis and management. Front Neurol 2017; 8: 686 CrossRef MEDLINE PubMed Central
e31.Keating GM: Tasimelteon: a review in non-24-hour sleep-wake disorder in totally blind individuals. CNS Drugs 2016; 30: 461–8 CrossRef MEDLINE
e32.Lockley SW, Dressman MA, Licamele L, et al.: Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet 2015; 386: 1754–64 CrossRef
e33.Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540–5 CrossRef MEDLINE
e34.Khatami R, Luca G, Baumann CR, et al.: The European Narcolepsy Network (EU-NN) database. J Sleep Res 2016; 25: 356–64 CrossRef MEDLINE
e35.Coelho FMS, Pradella-Hallinan M, Predazzoli Neto M, Bittencourt LRA, Tufik S: Prevalence of the HLA-DQB1*0602 allele in narcolepsy and idiopathic hypersomnia patients seen at a sleep disorders outpatient unit in São Paulo. Rev Bras Psiquiatr 2009; 31:10–4 CrossRef
e36.Liblau RS, Vassalli A, Seifinejad A, Tafti M: Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol 2015; 14: 318–28 CrossRef
e37.Murer T, Imbach LL, Hackius M, et al.: Optimizing MSLT specificity in narcolepsy with cataplexy. Sleep. 2017; 40 (12) CrossRef MEDLINE
e38.Kritikou I, Vgontzas AN, Rapp MA, Bixler EO: Anti-Ma1– and Anti-Ma2-associated encephalitis manifesting with rapid eye movement sleep disorder and narcolepsy with cataplexy: a case report. Biol Psychiatry 2018; 83: e39–40 CrossRef MEDLINE
e39.Billiard M, Bassetti C, Dauvilliers Y, et al.: EFNS guidelines on management of narcolepsy. Eur J Neurol 2006; 13: 1035–48 CrossRef MEDLINE
e40.US Narcolepsy Multicentre Study: Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998; 43: 88–97 CrossRef MEDLINE
e41.Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M: The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use. Sleep Med 2017; 33: 125–9 CrossRef MEDLINE
e42.The U.S. Xyrem Multicenter Study Group: A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25: 42–9.
e43.Schachter M, Parkes JD: Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry 1980; 43: 171–4 CrossRef MEDLINE PubMed Central
e44.Smith M, Parkes J, Dahlitz M: Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res 1996; 5: 217.
e45.Mayer G, Benes H, Young P, Bitterlich M, Rodenbeck A: Modafinil in the treatment of idiopathic hypersomnia without long sleep time—a randomized, double-blind, placebo-controlled study. J Sleep Res 2015; 24: 74–81 CrossRef MEDLINE
e46.Stubbs B, Vancampfort D, Veronese N, et al.: The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: a systematic review and meta-analysis. J Affect Disord 2016; 197: 259–67 CrossRef MEDLINE
e47.Guichard K, Marti-Soler H, Micoulaud-Franchi JA, et al.: The NoSAS score: a new and simple screening tool for obstructive sleep apnea syndrome in depressive disorder. J Affect Disord 2017; 227: 136–40 CrossRef MEDLINE
e48.Hermann DM, Bassetti CL: Role of sleep-disordered breathing and sleep-wake disturbances for stroke and stroke recovery. Neurology 2016; 87: 1407–16 CrossRef MEDLINE PubMed Central
e49.Sahlin C, Sandberg O, Gustafson Y, et al.: Obstructive sleep apnea is a risk factor for death in patients with stroke. Arch Intern Med 2008; 168: 297 CrossRef MEDLINE
e50.Gorenek (chair) B, Pelliccia (co-chair) A, Benjamin EJ, et al.: European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society. Eur J Prev Cardiol 2017; 24: 4–40 CrossRef
e51.Chihorek AM, Abou-Khalil B, Malow BA: Obstructive sleep apnea is associated with seizure occurrence in older adults with epilepsy. Neurology 2007; 69: 1823–7 CrossRef MEDLINE
e52.Petit D, Pennestri M-H, Paquet J, et al.: Childhood sleepwalking and sleep terrors. JAMA Pediatr 2015; 169: 653 CrossRef MEDLINE
e53.Schenck CH, Boyd JL, Mahowald MW: A parasomnia overlap disorder involving sleepwalking, sleep terrors, and REM sleep behavior disorder in 33 polysomnographically confirmed cases. Sleep 1997; 20: 972–81 CrossRef MEDLINE
e54.Hwang T-J, Ni H-C, Chen H-C, Lin Y-T, Liao S-C: Risk predictors for hypnosedative-related complex sleep behaviors: a retrospective, cross-sectional pilot study. J Clin Psychiatry 2010; 71: 1331–5 CrossRef MEDLINE
e55.Hoque R, Chesson AL: Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med 2009; 5: 471–6.
e56.Halsband C, Zapf A, Sixel-Döring F, Trenkwalder C, Mollenhauer B: The REM sleep behavior disorder screening questionnaire is not valid in de novo parkinson’s disease. Mov Disord Clin Pract 2018; 5: 171–6 CrossRef MEDLINE PubMed Central
e57.Iranzo A, Molinuevo JL, Santamaria J, et al.: Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006; 5: 572–7 CrossRef
e58.Iranzo A, Santamaría J, Valldeoriola F, et al.: Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 2017; 82: 419–28 CrossRef MEDLINE
e59.Berger K, Luedemann J, Trenkwalder C, John U, Kessler C: Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004; 164: 196–202 CrossRef MEDLINE
e60.Happe S, Vennemann M, Evers S, Berger K: Treatment wish of individuals with known and unknown restless legs syndrome in the community. J Neurol 2008; 255: 1365–71 CrossRef MEDLINE
e61.Szentkirályi A, Völzke H, Hoffmann W, Trenkwalder C, Berger K: Multimorbidity and the risk of restless legs syndrome in 2 prospective cohort studies. Neurology 2014; 82: 2026–33 CrossRef MEDLINE
e62.Trenkwalder C, Allen R, Högl B, Paulus W, Winkelmann J: Restless legs syndrome associated with major diseases: a systematic review and new concept. Neurology 2016; 86: 1336–43 CrossRef MEDLINE PubMed Central
e63.Kolla BP, Mansukhani MP, Bostwick JM: The influence of antidepressants on restless legs syndrome and periodic limb movements: a systematic review. Sleep Med Rev 2018; 38: 131–40 CrossRef MEDLINE
e64.Trenkwalder C, Allen R, Högl B, et al.: Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol 2018; 17: 994–1005 CrossRef
e65.Trotti LM, Bhadriraju S, Becker LA: Iron for restless legs syndrome. Cochrane Database Syst Rev 2012; 5: CD007834 CrossRef MEDLINE PubMed Central MEDLINE
e66.Walters AS, Wagner ML, Hening WA, et al.: Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993; 16: 327–32 CrossRef